Composition and skincare product to inhibit the TRPV1 pathway and reduce skin irritation

Abstract

The present invention provides a composition for inhibiting the TRPV1 pathway and reducing skin irritation, comprising camellia extract and purslane extract, the mass ratio of camellia extract to purslane extract being 0.01-10:0.01-10. The composition of the present invention for inhibiting the TRPV1 pathway and reducing skin irritation comprises camellia extract and purslane extract, which inhibit the TRPV1 pathway. Both exhibit a synergistic effect in increasing the irritation response threshold, reducing the skin sensitivity reaction, and relieving tingling, itching, and burning sensations of the skin due to TRPV1 channel activation.

Description

Title of the invention: Composition and skin care product for inhibiting the TRPV1 pathway and reducing skin irritation Technical field

[0001] The present invention belongs to the field of daily cosmetic technology, and particularly relates to a composition for inhibiting the TRPV1 pathway and reducing skin irritation and a skin care product for inhibiting the TRPV 1 pathway and reducing skin irritation. TECHNICAL CONTEXT

[0002] The skin is the organ that covers the surface of the human body and is one of the most important organs, which plays a role in protecting the human body from the external environment and external irritations and maintaining the water balance of the human body. Strong irritation on the skin is likely to cause damage to the skin's surface barrier and cause a series of immune responses, and at the same time, the nerve endings on the skin surface receive irritation signals and send them to neurons, causing a series of sensations such as tingling, itching, burning, etc. There is an irritation threshold for nerve endings to receive irritation signals, when irritation is below the threshold, no signaling will occur and no response will occur.Over-response of nerves may cause hypersensitive reactions and mild irritation may cause reactions such as tingling, itching, burning, etc. Sensitive skin may react more strongly to minor disturbances due to barrier damage, exposure of nerve endings or excessive activity of nerve endings.

[0003] Transient receptor potential vanilloid subfamily 1 (TRPV1) channel is a non-selective cation channel that, once activated, causes an inward flow of extracellular calcium ions, resulting in an increase in intracellular calcium concentration, which in turn mediates a series of physiological or pathological responses. In recent years, the TRPV1 channel has been shown to have a significant effect on stinging, itching, and burning. Exogenous administration of TRPV1 antagonists can effectively reduce the skin stress response and improve the skin barrier.

[0004] Camellia (scientific name: Camellia sp.), also known as Japanese camellia, contains over 700 compounds that have been found to promote health human, including flavonoids and polyphenols, camellia has been shown to have a variety of physiological activities. Camellia extract can inhibit the production of tyrosinase, thereby evening out skin tone, resisting UVB-induced photoaging, and reducing skin damage caused by environmental pollution.

[0005] Purslane, also known as Portulaca oleracea, is a commonly used traditional Chinese medicine, and its young stems and leaves can also be used in dishes. It is rich in amino acids, proteins, polysaccharides and other components. Studies have shown that its extracts and chemical components exhibit biological activities such as anti-inflammatory, antidiabetic, antioxidant, anticancer and antibacterial activities, and exhibit effects of reducing skin redness and helping to improve the skin barrier.

[0006] Based on this, the present invention provides a composition for inhibiting the TRPV1 pathway and reducing skin irritation, capable of inhibiting stinging, itching and burning of the skin due to activation of the TRPV1 channel. DISCLOSURE OF THE INVENTION

[0007] A first object of the present invention is to provide a composition for inhibiting the TRPV1 pathway and reducing skin irritation, in order to solve the technical problem of the deficiency of existing cosmetics in reducing skin irritation by inhibiting the TRPV1 pathway.

[0008] A second object of the present invention is to provide a skin care product for inhibiting the TRPV1 pathway and reducing skin irritation.

[0009] The objects of the present invention are achieved by a following technical solution:

[0010] A composition for inhibiting the TRPV 1 pathway and reducing skin irritation comprises a camellia extract and a purslane extract, the mass ratio of the camellia extract to the purslane extract is 0.01-10: 0.01-10.

[0011] Furthermore, the mass ratio of camellia extract to purslane extract is 1-10: 1-10.

[0012] In the composition of the present invention for inhibiting the TRPV 1 pathway and reducing skin irritation, camellia extract is rich in polyphenols and flavonoids and has good antioxidant activity. Purslane extract is rich in flavonoids, alkaloids and polysaccharides and has good antibacterial, antioxidant and anti-inflammatory effects. The present invention uses camellia extract and purslane extract and has an inhibitory effect on the TRPV1 channel, thereby increasing the irritation response threshold and reducing the skin sensitivity reaction. A combination of the two extracts has a synergistic effect for inhibiting tingling, itching and burning of the skin associated with activation of the TRPV1 channel.

[0013] In the present invention, the content of protocatechuic acid in the camellia extract is not less than 1%.

[0014] The present invention can be improved as follows, the camellia extract is prepared by the following steps:

[0015] (1) Dry the camellia, remove impurities and pulverize at 20-100 mesh to to use ;

[0016] (2) Add 10 to 30 times by weight of the mixture of water and ethanol, make a decoction at reflux under atmospheric pressure, filter, and concentrate the filtrate to 80% - 200% by weight of the camellia by distillation under reduced pressure to obtain a crude extract;

[0017] (3) Add 10-20% by weight of the adsorbent relative to the crude extract, stir at microwave until colorless, filter, collect the filtrate and continue to distill under reduced pressure to dry to obtain the camellia extract.

[0018] Furthermore, the volume ratio of water to ethanol in the water and ethanol mixture is 20:80 - 80:20.

[0019] Preferably, the volume ratio of water to ethanol is 40:60 - 60:40.

[0020] The reflux decoction temperature is 80-95°C.

[0021] In the present invention, the content of polysaccharides in the purslane extract is not less than 10%.

[0022] The present invention can be improved as follows, the purslane extract is prepared by the following steps:

[0023] (1) Dry the purslane, remove impurities and pulverize to 20-100 mesh to to use ;

[0024] (2) Add 10 to 60 times by weight of the mixture of water and ethanol, make a decoction at reflux under atmospheric pressure, filter, and concentrate the filtrate to 80% - 200% by weight of purslane by distillation under reduced pressure to obtain a crude extract;

[0025] (3) Add 10-20% by weight of the adsorbent relative to the crude extract, stir at microwave until colorless, filter, collect the filtrate and continue to distill under reduced pressure to dry to obtain the purslane extract.

[0026] Furthermore, the mass ratio of the mixture of water and ethanol to purslane is 40 -60.

[0027] Furthermore, the volume ratio of water to ethanol is 10:90 - 90:20.

[0028] Preferably, the volume ratio of water to ethanol is 70:30 - 90:20.

[0029] In addition, the reflux decoction temperature is 80 - 95 ° C.

[0030] Preferably, the reflux decoction temperature is 90 - 95 ° C.

[0031] A skin care product for inhibiting the TRPV1 pathway and reducing skin irritation comprises the composition for inhibiting the TRPV 1 pathway and reducing skin irritation skin above.

[0032] In addition, the skin care product for inhibiting the TRPV1 pathway and reducing skin irritation further comprises the following components in mass percentage: glycerol 1% - 5%, butylene glycol 1% - 5%, allantoin 0.1% - 1%, thickener 0.1% - 1%, sodium hyaluronate 0.01% - 0.5%, squalane 0.1% - 5%, emulsifier 0.5% - 1.5% and water qs

[0033] In the present invention, the thickener is one or more of carbomer and its neutralizing agent, xanthan gum, an acrylate / C10-30 alkyl acrylate crosspolymer (copolymer).

[0034] The emulsifier is one or more of oliem 1000 and Montanov L.

[0035] Compared to existing techniques, the present invention has the following beneficial effects:

[0036] (1) The composition of the present invention for inhibiting the TRPV 1 pathway and reducing Skin irritation includes Camellia extract and Purslane extract inhibiting the TRPV1 pathway, both exhibit a synergistic effect to increase the response threshold to irritations, reduce skin sensitivity reaction and relieve skin stinging, itching and burning due to the activation of the TRPV1 channel.

[0037] (2) The composition of the present invention for inhibiting the TRPV 1 pathway and reducing skin irritation, combined with its applications in cosmetics, can be more widely used in cosmetics and medicines to solve many skin problems. DESCRIPTION OF FIGURES

[0038] [Fig-1] is a view illustrating the fluorescence detection of TRPV 1 protein on the blank control (BC);

[0039] [Fig.2] is a view illustrating the fluorescence detection of the TRPV 1 protein on the negative control (NC);

[0040] [Fig.3] is a view illustrating the fluorescence detection of the TRPV 1 protein on the negative control (4-tert-butylcyclohexanol).

[0041] [Fig.4] is a view illustrating the fluorescence detection of the TRPV 1 protein of comparative example 1;

[0042] [Fig.5] is a view illustrating the fluorescence detection of the TRPV 1 protein of comparative example 2;

[0043] [Fig.6] is a view illustrating the fluorescence detection of the TRPV 1 protein of the composition of Example 1 for inhibiting the TRPV1 pathway and reducing skin irritation;

[0044] [Fig.7] is a view illustrating the fluorescence detection of the TRPV 1 protein of the composition of Example 2 to inhibit the TRPV1 pathway and reduce irritation of the skin ;

[0045] [Fig.8] is a view illustrating the fluorescence detection of the TRPV1 protein of the composition of Example 3 for inhibiting the TRPV1 pathway and reducing skin irritation;

[0046] [Fig.9] is a view illustrating the results of the dosage of the TRPV 1 protein of different working liquids;

[0047] [Fig. 10] is a view illustrating the results of capsaicin burning on the skin care product of Comparative Example 1;

[0048] [Fig. 11] is a view illustrating the results of capsaicin burning on the skin care product of Comparative Example 2;

[0049] [Fig. 12] is a view illustrating the results of capsaicin burning on the skin care product of Example 1;

[0050] [Fig. 13] is a view illustrating the results of capsaicin burning on the skin care product of Example 2;

[0051] [Fig. 14] is a view illustrating the results of capsaicin burning on the skin care product of Example 3. DETAILED DESCRIPTION OF THE UTILITY CERTIFICATE

[0052] The present invention will be described in more detail below with reference to the embodiments, so that those skilled in the art can better understand and implement the solution of the present invention. In the embodiments, the content of protocatechuic acid in the camellia extract is not less than 1%, and the content of polysaccharides in the purslane extract is not less than 10%.

[0053] Camellia extract is prepared by the following steps:

[0054] (1) Dry the camellia, remove impurities and pulverize at 20-100 mesh to to use ;

[0055] (2) Add 10 to 30 times by weight of the mixture of water and ethanol, the volume ratio water to ethanol in the mixture of water and ethanol being 50:50, make a reflux decoction at 85°C under atmospheric pressure, filter, and concentrate the filtrate to 150% by weight of the camellia by distillation under reduced pressure to obtain a crude extract;

[0056] (3) Add 15% by weight of activated carbon particles as adsorbent relative to to the crude extract, stir in the microwave until colorless, filter, collect the filtrate and continue to distill under reduced pressure to dry to obtain the camellia extract.

[0057] Purslane extract is prepared by the following steps:

[0058] (1) Dry the purslane, remove impurities and pulverize to 20-100 mesh to to use ;

[0059] (2) Add 40 to 60 times by weight of the mixture of water and ethanol, the volume ratio water to ethanol in the mixture of water and ethanol being 80:20, make a reflux decoction at 90°C under atmospheric pressure, filter, and concentrate the filtrate to 150% by weight of purslane by distillation under reduced pressure to obtain a crude extract;

[0060] (3) Add 20% by weight of activated carbon particles as adsorbent by relative to the crude extract, stir in the microwave until colorless, filter, collect the filtrate and continue to distill under reduced pressure to dry to obtain the purslane extract. Example 1

[0061] A composition for inhibiting the TRPV1 pathway and reducing skin irritation (Redsnow Relief), comprises a camellia extract and a purslane extract, the mass percentage of the camellia extract being 0.0125%, and the mass percentage of the purslane extract being 0.004375%.

[0062] A method of preparing the composition for inhibiting the TRPV 1 pathway and reducing skin irritation described as above, comprises the following steps:

[0063] dissolve the powdered camellia extract in water to prepare a solution of the 1% camellia extract, i.e., camellia redsnow extract, dissolve the powdered purslane extract in water to prepare a solution of the 3.5% purslane extract, i.e., purslane protulaca extract, dilute the camellia redsnow extract to a mass fraction of 0.025%, dilute the purslane protulaca extract to a mass fraction of 0.00875%, and then mix the two in equal amounts to obtain the composition for inhibiting the TRPV 1 pathway and reducing skin irritation (Redsnow Relief).

[0064] A skin care product for inhibiting the TRPV 1 pathway and reducing skin irritation is composed of the following components in mass percentage: Number Name of primary material Percentage 1 Glycerol 3% 2 Butanediol 5% 3 Sodium hyaluronate 0.02% 4 Allantoin 0.1% 5 Carbomer 0.2% 6 Camellia redsnow extract 1.25% 7 Purslane protulaca extract 0.125% 8 Olivem 1000 1% 9 Squalane 3% 10 Arginine 0.2% 11 Water qs Example 2

[0065] A composition for inhibiting the TRPV1 pathway and reducing skin irritation (Redsnow Relief), comprises a camellia extract and a purslane extract, the mass percentage of the camellia extract being 0.006%, and the mass percentage of the purslane extract being 0.021%.

[0066] A method for preparing the composition for inhibiting the TRPV 1 pathway and reducing skin irritation described as above, comprises the following steps: dissolving the powdered camellia extract in water to prepare a solution of the 1% camellia extract, i.e., redsnow camellia extract, dissolving the powdered purslane extract in water to prepare a solution of the 3.5% purslane extract, i.e., protulaca purslane extract, diluting the redsnow camellia extract to a mass fraction of 0.012%, diluting the protulaca purslane extract to a mass fraction of 0.042%, and then mixing the two in equal amounts to obtain the composition for inhibiting the TRPV 1 pathway and reducing skin irritation (Redsnow Relief).

[0067] A skin care product for inhibiting the TRPV 1 pathway and reducing skin irritation is composed of the following components in mass percentage: Number Name of primary material Percentage 1 Glycerol 3% 2 Butanediol 5% 3 Sodium hyaluronate 0.02% 4 Allantoin 0.1% 5 Carbomer 0.2% 6 Camellia redsnow extract 0.6% 7 Purslane protulaca extract 0.6% 8 Olivem 1000 1% 9 Squalane 3% 10 Arginine 0.2% 11 Water qs Example 3

[0068] A composition for inhibiting the TRPV 1 pathway and reducing skin irritation (Redsnow Relief), comprises a camellia extract and a purslane extract, the mass percentage of the camellia extract being 0.0006%, and the mass percentage mass of purslane extract being 0.021%.

[0069] A method for preparing the composition for inhibiting the TRPV1 pathway and reducing skin irritation described as above, comprises the following steps: dissolving the powdered camellia extract in water to prepare a solution of the 1% camellia extract, i.e., redsnow camellia extract, dissolving the powdered purslane extract in water to prepare a solution of the 3.5% purslane extract, i.e., protulaca purslane extract, diluting the redsnow camellia extract to a mass fraction of 0.0012%, diluting the protulaca purslane extract to a mass fraction of 0.042%, and then mixing the two in equal amounts to obtain the composition for inhibiting the TRPV 1 pathway and reducing skin irritation (Redsnow Relief).

[0070] A skin care product for inhibiting the TRPV 1 pathway and reducing skin irritation is composed of the following mass percentage components: Number Name of primary material Percentage 1 Glycerol 3% 2 Butanediol 5% 3 Sodium hyaluronate 0.02% 4 Allantoin 0.1% 5 Carbomer 0.2% 6 Camellia redsnow extract 0.06% 7 Purslane protulaca extract 0.6% 8 Olivem 1000 1% 9 Squalane 3% 10 Arginine 0.2% 11 Water qs Comparative example 1

[0071] A composition comprises a camellia extract at a mass fraction of 0.0125%. It is prepared according to the following steps: dissolving the powdered camellia extract in water to prepare a solution of the camellia extract at 1%, i.e. the redsnow camellia extract, and diluting the redsnow camellia extract to a mass fraction of 0.0125% to obtain.

[0072] A skin care product comprising the above composition has a difference from Example 1, the difference being that it does not comprise purslane extract and the containers of camellia extract and water are different. Comparative example 2

[0073] A composition comprises a purslane extract at a mass fraction of 0.004375%. It is prepared according to the following steps: dissolving the powdered purslane extract in water to prepare a solution of the purslane extract at 3.5%, i.e., purslane protulaca extract, and diluting the purslane protulaca extract to a mass fraction of 0.004375% to obtain.

[0074] A skin care product comprising the above composition has a difference from Example 1, the difference being that it does not comprise camellia extract and the containers of purslane extract and water are different. Performance tests

[0075] 1. Test of the TRPV1 receptor protein on keratinocytes

[0076] Keratinocytes are the most important cells found on the superficial layer of the skin, constituting 90% of the epidermal cells of the skin. By inhibiting the expression of epidermal cells, the activation of the TRPV1 pathway induced by skin irritation is reduced. For the verification of the inhibition of the TRPV1 pathway, the method of detecting the content of TRPV1 receptor (protein) in keratinocytes was used, which allows detecting the inhibition on the TRPV1 pathway by testing the inhibition of the expression of the TRPV1 receptor protein.

[0077] For this, the cytotoxic concentrations of Camellia Redsnow extract and Purslane Protulaca extract were detected first, and the specific results were shown in Tables 1 and 2.

[0078] Table 1 Cytotoxic concentrations of Redsnow Camellia extract Concentration gradient 1 2 3 4 5 6 7 8 PC Control 0.078 1 0.156 3 0.312 5 0.625 1.25 2.5 5 10 10%D MSO / Vi ab ilit é cel lui air e Moye nne 1 2 .78 .70 40% 108.8 1% 108.1 9% 104.6 5% 84.9 4% 79.6 7% 35.3 9% 1.8% 100 % SD 3.58 % 2.40 % 3.58 % 1.56 % 8.82 % 8.27 % 1.27 % % 0.12% 7.52 % Value rp 1.000 0.127 0.141 0.138 0.525 0.07 9 0.01 0 0.00 0 0.000 / Table 2 Cytotoxic concentrations of purpier protulaca extract Ion concentration gradient 1 2 3 4 5 6 7 8 PC Control 0.078 1 0.156 3 0.312 5 0.625 1.25 2.5 5 10 10%D MSO / Vi ab ilit é cel lui air e Average 100.0 10.6% 99.58 % 96.39 % 88.62 % 84.66 % 73.14 % 37.47 % 1.8% 100 % SD 3.18 % 3.27 % 5.23 % 3.86 % 6.38 % 4.23 % H 5.48 % 0.12% 7.52 % P -Value 1.000 0.773 0.941 0.501 0.116 0.036 0.007 0.000 0.000 /

[0079] The data in Tables 1 and 2 show that the test concentration of Camellia redsnow extract is not more than 1.25% and the test concentration of Purslane protulaca extract is not more than 0.625%.

[0080] Seed the keratinocytes at a seeding density of 1.8x105 / well in a 6-well plate and incubate overnight in an incubator (37 °C, 5% CO2). The use of the tested working fluid is shown in Table 3 below.

[0081] Table 3 Use of the tested working fluid Test Groups Sample Information Detection System Sample Name Sample Concentration Irritation Conditions Blank Control (BC) / Negative Control (NC) / CAP (15pM) Positive Control 4-tert-butylcy clohexanol Sample Group Example 1 Camellia redsnow extract 1.25% and Purslane protulaca extract 0.125% Example 2 Camellia redsnow extract 0.6% and Purslane protulaca extract 0.6% Example 3 Camellia redsnow extract 0.06% and Purslane protulaca extract 0.6% Comparative Example 1 Camellia redsnow 1.25% Comparative Example 2 Purslane protulaca extract 0.125%

[0082] According to the test protocol in the table above, when the cell plating rate in the 6-well plate reaches 40% to 50%, perform administration in groups at an administration dose of 2 ml / well, 3 wells for each group. After administration, incubate the 6-well plate in an incubator (37°C, 5% CO2) for 24 h.

[0083] TRPV1 detection: treat with 4% paraformaldehyde to fix for 30 minutes, At the end of fixation, perform immunofluorescence detection for the capsaicin receptor (TRPV1), observe under a microscope and take pictures, acquire images and analyze them.

[0084] Plot the graphs using GraphPad Prism, and express the results as Mean+SD. Compare the different groups using t-test statistical analysis. The statistical analysis was two-fold. P<0.05 represents a significant difference and P<0.01 represents a highly significant difference.

[0085] Based on the test protocol, TRPV 1 detection was performed according to the steps of immunofluorescence operation, and the results were shown in the view of the Fluorescence detection of TRPV1 protein in Figures 1 to 8, and the evolution trend was shown in [Fig.9]. The figures (# represents that the NC group has a significant difference compared with the BC group, * represents p<0.05, ** represents p<0.01, **** represents p<0.001) show that the use of single camellia extract and the use of single purslane extract has an inhibitory effect on TRPV1. When the two are combined at a certain proportion, they exhibit a synergistic effect and the inhibition effect is more significant, Example 2 has the best effect. This shows that the composition of these two plant extracts can effectively inhibit TRPV1 channels, thus playing a role in reducing skin irritation.

[0086] 2. Capsaicin test on the human body

[0087] Capsaicin is a classic irritant agent that activates TRPV1, which causes stinging, burning, and redness when it comes into contact with the human body. In this test, 0.01% capsaicin was used as an irritant to irritate both sides of the nasolabial fold, and then the test samples were administered on one side, and the improvement was compared with the white area. The test samples are the skin care products prepared in Examples 1 to 3 and Comparative Examples 1 and 2, respectively.

[0088] During the test, apply a filter paper (diameter of about 0.8 cm) soaked with 50 μL of 0.01% capsaicin aqueous solution to each of the two sides of the subject's nasolabial fold, and when the subject judged that the sensory score of both sides of the nasolabial fold > 3 points (moderate sensation and above), remove the filter paper. Apply 50 μL of test sample by the operator to one side of the test area, no treatment on the other side (blank control).Before sample administration (after capsaicin irritation, before sample administration) and 0.5 min, 5 min, 10 min, 15 min, 20 min and 30 min after sample administration, subjects subjectively evaluated the burning pain in the nasolabial fold and rated it in 5 points, the rating standard is: 0 points corresponds to no sensation, 1 point corresponds to a just perceptible sensation, 2 points corresponds to a slightly perceptible sensation, 3 points corresponds to a moderately perceptible sensation, 4 points corresponds to a severe perceptible sensation and 5 points corresponds to pain. The specific results are shown in Figures 10 to 14. .

[0089] Figures 10 to 14 show that the burning sensation caused by capsaicin was improved in the comparative examples and the embodiment examples, the effect of relieving irritation in the embodiment examples was better than that in the comparative examples, among which Example 2 exhibits the best effect, with the burning pain significantly reduced compared to the blank control at 5min.

[0090] The processes for implementing the present invention are described through the above embodiments, but the embodiments of the present invention are not limited thereto, the person skilled in the art can achieve the purpose of the present invention by complying with the contents disclosed in the present invention, any modifications and variations proposed based on the idea of ​​the present invention shall be included within the scope of protection of the present invention, and the scope of protection shall be defined by the appended claims.

Claims

Claims

1. A composition for inhibiting the TRPV1 pathway and reducing skin irritation, characterized in that it comprises a camellia extract and a purslane extract, the mass ratio of the camellia extract to the purslane extract being 0.01-10:0.01-10.

2. A composition for inhibiting the TRPV1 pathway and reducing skin irritation according to claim 1, characterized in that the mass ratio of camellia extract to purslane extract is 1-10: 1-10.

3. 3.Composition for inhibiting the TRPV1 pathway and reducing skin irritation according to claim 2, characterized in that the content of protocatechuic acid in the camellia extract is not less than 1%.

4. 4. A composition for inhibiting the TRPV1 pathway and reducing skin irritation according to claim 3, characterized in that, the camellia extract is prepared by the following steps: (1) Drying the camellia, removing impurities and pulverizing to 20-100 mesh for use; (2) Adding 10-30 times by weight of the mixture of water and ethanol, refluxing decoction under atmospheric pressure, filtering, and concentrating the filtrate to 80%-200% by weight of the camellia by distillation under reduced pressure to obtain a crude extract; (3) Adding 10-20% by weight of the adsorbent relative to the crude extract, stirring in a microwave until colorless, filtering, collecting the filtrate and continuing to distill under reduced pressure to dry to obtain the camellia extract.

5. A composition for inhibiting the TRPV1 pathway and reducing skin irritation according to claim 4, characterized in that the volume ratio of water to ethanol in the mixture of water and ethanol is 20:80 - 80:20; and the reflux decoction temperature is 80 - 95 °C.

6. A composition for inhibiting the TRPV1 pathway and reducing skin irritation according to any one of claims 3 to 5, characterized in that the polysaccharide content in the purslane extract is not less than 10%.

7. A composition for inhibiting the TRPV1 pathway and reducing skin irritation according to claim 6, characterized in that, the purslane extract is prepared by the following steps: (1) Drying the purslane, removing impurities and pulverizing to 20-100 mesh for use; (2) Add 10-60 times by weight of the mixture of water and ethanol, reflux decoct under atmospheric pressure, filter, and concentrate the filtrate to 80%-200% by weight of the purslane by distillation under reduced pressure to obtain a crude extract; (3) Add 10-20% by weight of the adsorbent relative to the crude extract, stir in the microwave until colorless, filter, collect the filtrate, and continue to distill under reduced pressure to dry to obtain the purslane extract.

8. A composition for inhibiting the TRPV1 pathway and reducing skin irritation according to claim 7, characterized in that the volume ratio of water to ethanol in the mixture of water and ethanol is 20:80 - 80:20; and the reflux decoction temperature is 80 - 95 °C.

9. A skin care product for inhibiting the TRPV1 pathway and reducing skin irritation, characterized in that it comprises the composition for inhibiting the TRPV1 pathway and reducing skin irritation according to any one of claims 1 to 8.

10. A skin care product for inhibiting the TRPV 1 pathway and reducing skin irritation according to claim 9, characterized in that the skin care product for inhibiting the TRPV 1 pathway and reducing skin irritation further comprises the following components in mass percentage: glycerol 1% - 5%, butylene glycol 1%-5%, allantoin 0.1%-1%, thickener 0.1%-1%, sodium hyaluronate 0.01%-0.5%, squalane 0.1%-5%, emulsifier 0.5%-1.5% and water qs5%.

Images